← Eichor
Study identifier: NCT05749289 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

Condition: SSTR Positive Tumors  ·  Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

PhasePhase 2/Phase 3
Planned participants400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors

This description comes directly from the study's public registry record.

Talk to the study team

Gouzhu Hou, M.D.  ·  15611145656  ·  15611145656@163.com

Xin Cheng, M.D.  ·  15120002998  ·  cxpumc@foxmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, Chao Yang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05749289